**Core Concept**
Chronic gout management involves urate-lowering therapy (ULT) to reduce serum urate levels, preventing further attacks and joint damage. However, patients with renal impairment require careful selection of ULT due to the risk of worsening kidney function.

**Why the Correct Answer is Right**
In patients with renal impairment, the preferred ULT is uricosuric agents like **probenecid** is not suitable due to the risk of worsening kidney function. **Febuxostat** is also not ideal as it is primarily metabolized by the liver but can cause renal impairment in patients with pre-existing kidney disease. **Lesinurad** is also not the best option as it is primarily excreted by the kidneys. **Benzbromarone** is a uricosuric agent that is still effective in patients with renal impairment, as it is primarily excreted in the bile.

**Why Each Wrong Option is Incorrect**
**Option A:** Probenecid is contraindicated in patients with renal impairment as it can worsen kidney function by increasing urate reabsorption in the proximal tubules.
**Option B:** Febuxostat can cause renal impairment in patients with pre-existing kidney disease, making it a less suitable option for patients with renal impairment.
**Option C:** Lesinurad is primarily excreted by the kidneys, making it a less suitable option for patients with renal impairment.
**Option D:** Benzbromarone is a less commonly used uricosuric agent that is still effective in patients with renal impairment.

**Clinical Pearl / High-Yield Fact**
When managing gout in patients with renal impairment, it's essential to consider the pharmacokinetics and pharmacodynamics of each ULT to minimize the risk of worsening kidney function.

**Correct Answer: D. Benzbromarone**